Pipeline

Avanir is innovation.

By focusing on disorders of the central nervous system, we strive to meet the needs of patients with innovative solutions. Below is an overview of our pipeline, updated quarterly.

AVP-923

Amyotrophic Lateral Sclerosis Bulbar Dysfunction
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
APPROVED

Description/Summary

The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-923 compared to placebo for the treatment of bulbar dysfunction in patients with ALS.

AVP-825

Acute Migraine in Pediatrics
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
APPROVED

Description/Summary

The objective of the study is to evaluate the safety and efficacy of AVP-825 compared to placebo in the acute treatment of migraine in adolescent patients, 12 through 17 years-of-age.

AVP-786

Agitation in Alzheimer’s disease
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
APPROVED

Description/Summary

The objectives of the studies are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type.

Residual Schizophrenia
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
APPROVED

Description/Summary

The objectives of this study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia on negative and positive symptoms and cognitive function.

Disinhibition in Dementia
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
APPROVED

Description/Summary

The objectives of the study are to evaluate the safety, tolerability, and efficacy of AVP-786 compared to placebo, for the treatment of disinhibition in patients with Neurodegenerative Disorders (NDD) including frontotemporal dementia, Alzheimer’s disease, progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies, vascular cognitive disorders, or Huntington’s disease.

Traumatic Brain Injury Behavioral Dysfunction
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
APPROVED

Description/Summary

The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of neurobehavioral disinhibition such as aggression, agitation, and irritability in patients with traumatic brain injury.

Disclaimer

 

Block 1 - Job Block

Medical Director, Clinical Development

Aliso Viejo, CA

The Medical Director, Clinical Development is responsible for the design, planning and medical oversight of clinical studies for all phases of development …

Continue Reading

Joel Modayil
Neuroscience Area Manager, Long Term Care

Director of Clinical Development
Block 2 - Job Block

Senior Clinical Research Associate

Aliso Viejo, CA

The Senior Clinical Research Associate will be responsible for initiation, monitoring and other tasks associated with the study management of clinical studies …

Continue Reading

Amy Kincaid
Senior Manager, Market Research

Senior Clinical Research Associate
Block 3 - Job Block

Corporate Controller

Aliso Viejo, CA

As a key leader in the Company’s finance organization, the Corporate Controller is responsible for managing the Company’s Accounting function …

Continue Reading

Tim Bareham
Field Sales Trainer-LTC

Corporate Controller
Block 4 - Job Block

Unlock the future of CNS treatment

Join our team of Innovators

Avanir employees are a diverse team of dedicated, accomplished professionals united by a common purpose: striving to make a change by developing innovative treatments for central nervous system (CNS) conditions.

View open opportunities at Avanir

Join our team of Innovators